Analyzing Auxilium Pharmaceuticals (AUXL) & Onconova Therapeutics (ONTX)

Auxilium Pharmaceuticals (NASDAQ: AUXL) and Onconova Therapeutics (NASDAQ:ONTX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Earnings and Valuation

This table compares Auxilium Pharmaceuticals and Onconova Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A N/A N/A N/A
Onconova Therapeutics $2.36 million 9.35 -$22.15 million ($2.35) -0.95

Auxilium Pharmaceuticals has higher revenue, but lower earnings than Onconova Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and target prices for Auxilium Pharmaceuticals and Onconova Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Onconova Therapeutics 0 0 4 0 3.00

Onconova Therapeutics has a consensus price target of $7.33, indicating a potential upside of 227.38%. Given Onconova Therapeutics’ higher probable upside, analysts plainly believe Onconova Therapeutics is more favorable than Auxilium Pharmaceuticals.

Institutional & Insider Ownership

26.8% of Onconova Therapeutics shares are owned by institutional investors. 27.3% of Onconova Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Auxilium Pharmaceuticals and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Onconova Therapeutics -762.13% -558.97% -85.62%


Onconova Therapeutics beats Auxilium Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About Auxilium Pharmaceuticals

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive News & Ratings for Auxilium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Leave a Reply